Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
October 14, 2019

Eli Lilly gets FDA approval for migraine drug Reyvow

Eli Lilly has secured approval from the US Food and Drug Administration (FDA) for its Reyvow (lasmiditan) for the acute treatment of migraine.

Image: Eli Lilly and Company's Corporate Centre in Indianapolis, Indiana. Photo: courtesy of Momoneymoproblemz.